Do advertisements for antihypertensive drugs in Australia promote quality prescribing? A cross-sectional study

Montgomery, Brett D.; Mansfield, Peter R.; Spurling, Geoffrey K.; Ward, Alison M.
January 2008
BMC Public Health;2008, Vol. 8 Issue 1, p167
Academic Journal
Background: Antihypertensive medications are widely prescribed by doctors and heavily promoted by the pharmaceutical industry. Despite strong evidence of the effectiveness and cost-effectiveness of thiazide diuretics, trends in both promotion and prescription of antihypertensive drugs favour newer, less cost-effective agents. Observational evidence shows correlations between exposure to pharmaceutical promotion and less ideal prescribing. Our study therefore aimed to determine whether print advertisements for antihypertensive medications promote quality prescribing in hypertension. Methods: We performed a cross-sectional study of 113 advertisements for antihypertensive drugs from 4 general practice-oriented Australian medical publications in 2004. Advertisements were evaluated using a quality checklist based on a review of hypertension management guidelines. Main outcome measures included: frequency with which antihypertensive classes were advertised, promotion of thiazide class drugs as first line agents, use of statistical claims in advertisements, mention of harms and prices in the advertisements, promotion of assessment and treatment of cardiovascular risk, promotion of lifestyle modification, and targeting of particular patient subgroups. Results: Thiazides were the most frequently advertised drug class (48.7% of advertisements), but were largely promoted in combination preparations. The only thiazide advertised as a single agent was the most expensive, indapamide. No advertisement specifically promoted any thiazide as a better first-line drug. Statistics in the advertisements tended to be expressed in relative rather than absolute terms. Drug costs were often reported, but without cost comparisons between drugs. Adverse effects were usually reported but largely confined to the advertisements' small print. Other than mentioning drug interactions with alcohol and salt, no advertisements promoted lifestyle modification. Few advertisements (2.7%) promoted the assessment of cardiovascular risk. Conclusion: Print advertisements for antihypertensive medications in Australia provide some, but not all, of the key messages required for guideline-concordant care. These results have implications for the regulation of drug advertising and the continuing education of doctors.


Related Articles

  • Money-Back Guarantee. Breitstein, Joanna // Pharmaceutical Executive;Jun2004, Vol. 24 Issue 6, p110 

    Reports that pharmaceutical firm Novartis AG has launched the biggest hypertension public relation campaign called Take Action for Healthy Blood Pressure. Market expansion effort in support of the Novartis' antihypertensive franchise; Basic components of the campaign; Different tools developed...

  • Pharmacy Experience With Facsimile Prescriptions. Huntzinger, Paul E. // Military Medicine;Nov2010, Vol. 175 Issue 11, p907 

    The purpose of this mixed qualitative/quantitative study was to review the impact of a policy to accept facsimile (fax) prescriptions as standard operating procedure. Between February and April 2009 the pharmacy processed 4,792 new prescriptions of which 363 (7.6%) were received through fax. Of...

  • Pharmacists tap Net. Callaghan, Dennis // eWeek;9/20/2004, Vol. 21 Issue 38, p34 

    The article focuses on internet-based prescriptions by pharmacists. Handwritten prescriptions hand-carried to pharmacies are still the norm, leading to an estimated 150 million callbacks a year to doctors by pharmacists questioning illegible handwritten prescriptions, as well as 7,000 patient...

  • Novel spectrophotometric method for the estimation of Nisoldipine in bulk and pharmaceutical dosage forms. Safhi, Mohammed M. // Der Pharma Chemica;2011, Vol. 3 Issue 4, p275 

    A new, simple and sensitive spectrophotometric method in ultraviolet region has been developed for the determination of nisoldipine in bulk and in pharmaceutical formulations. Nisoldipine exhibits absorption maxima at 237 nm. Developed method obeyed the Beer's law in the concentration range of 4...

  • UK sues Servier over alleged blocking of generic substitute. Dyer, Clare // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;6/18/2011, Vol. 342 Issue 7811, p1330 

    No abstract available.

  • Arete Brings In $51M For New Hypertension Class.  // Bioworld Week;5/28/2007, Vol. 15 Issue 22, p4 

    The article reports that the Arete Therapeutics Inc. of Hayward, California has added $35 million to its Series A financing round, raising a total of $51 million financing for its new class of drugs targeting hypertension and other conditions. The report says that the company was founded on the...

  • Enhancement of Carvedilol Dissolution; Surface Solid Dispersion Versus Solid Dispersion. Essa, Ebtessam Ahmed // Asian Journal of Pharmaceutics (Medknow Publications & Media Pvt;Oct-Dec2015, Vol. 9 Issue 4, p283 

    The aim of this work was to improve the aqueous solubility of carvedilol (CRV), poorly water soluble drug, using surface solid dispersion (SSD) technique. Drug was deposited over the surface of a hydrophilic, water-insoluble carrier (Avicel pH 101) by solvent evaporation. Pluronic F68 was added...

  • Application of Stability Indicating TLC-Densitometric methods for the Determination of two Antihypertensive Drug Combinations. Shokry, Engy; Kawy, Mohamed Abdel; El-Gendy, Ahmed Emad // Current Science International;2014, Vol. 3 Issue 4, p381 

    Introduction: Moexipril hydrochloride (Mox) and fosinopril (Fos), each of them in combination with hydrochlorothiazide are of the most commonly used antihypertensive combinations. Aim: To develop a stability indicating TLC densitometry for the determination of the drugs of interest. Materials...

  • Pharma update.  // World of Irish Nursing & Midwifery;Dec2005, Vol. 13 Issue 11, p52 

    Presents an update on the pharmaceutical industry in Ireland as of December 2005. Launch of triapin, a dual action antihypertensive drug by Sanofi-Aventis; Decision of Yamanouchi to withdraw some of its pharmaceutical products from the Irish market.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics